Scioderm
Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions.
primaryTopic
Scioderm
Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions.
has abstract
Scioderm, acquired by Amicus T ...... cy (EMA) for its EB treatment.
@en
industry
Link from a Wikipage to an external page
Wikipage page ID
47,655,347
Wikipage revision ID
699,318,792
brands
founders
Robert Coull, CA, CBV
Robert Ryan, Ph.D.
hq location city
products
SD-101 for epidermolysis bullosa
subject
hypernym
comment
Scioderm, acquired by Amicus T ...... erage of blisters and lesions.
@en
label
Scioderm
@en
wasDerivedFrom
isPrimaryTopicOf
name
Scioderm
@en